PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

被引：0
|
作者：
Black, J. D. [1 ]
Lopez, S. [1 ]
Cocco, E. [1 ]
Bellone, S. [1 ]
Altwerger, G. [1 ]
Schwab, C. L. [1 ]
English, D. P. [1 ]
Bonazzoli, E. [1 ]
Predolini, F. [1 ]
Ferrari, F. [1 ]
Ratner, E. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Schwartz, P. E. [1 ]
Santin, A. D. [1 ]
机构：
[1] Yale Univ, New Haven, CT 06520 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 139卷 / 03期
关键词：
D O I：
10.1016/j.ygyno.2015.09.058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：596 / 596
页数：1
相关论文
共 50 条
  • [1] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Black, Jonathan D.
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Altwerger, Gary
    Schwab, Carlton L.
    English, Diana P.
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2015, 113 (07) : 1020 - 1026
  • [2] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Jonathan D Black
    Salvatore Lopez
    Emiliano Cocco
    Stefania Bellone
    Gary Altwerger
    Carlton L Schwab
    Diana P English
    Elena Bonazzoli
    Federica Predolini
    Francesca Ferrari
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E Schwartz
    Alessandro D Santin
    British Journal of Cancer, 2015, 113 : 1020 - 1026
  • [3] Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
    Jonathan D Black
    Salvatore Lopez
    Emiliano Cocco
    Stefania Bellone
    Gary Altwerger
    Carlton L Schwab
    Diana P English
    Elena Bonazzoli
    Federica Predolini
    Francesca Ferrari
    Elena Ratner
    Dan-Arin Silasi
    Masoud Azodi
    Peter E Schwartz
    Alessandro D Santin
    British Journal of Cancer, 2015, 113 : 1641 - 1641
  • [4] PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas (vol 113, pg 1020, 2015)
    Black, Jonathan D.
    Lopez, Salvatore
    Cocco, Emiliano
    Bellone, Stefania
    Altwerger, Gary
    Schwab, Carlton L.
    English, Diana P.
    Bonazzoli, Elena
    Predolini, Federica
    Ferrari, Francesca
    Ratner, Elena
    Silasi, Dan-Arin
    Azodi, Masoud
    Schwartz, Peter E.
    Santin, Alessandro D.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1641 - 1641
  • [5] Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
    Pelligra, Silvia
    Buza, Natalia
    Hui, Pei
    Bellone, Stefania
    Zeybek, Burak
    Ratner, Elena
    Schwartz, Peter E.
    Scambia, Giovanni
    Santin, Alessro D.
    GYNECOLOGIC ONCOLOGY REPORTS, 2020, 32
  • [6] Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
    Lopez, Salvatore
    Schwab, Carlton L.
    Cocco, Emiliano
    Bellone, Stefania
    Bonazzoli, Elena
    English, Diana P.
    Schwartz, Peter E.
    Rutherford, Thomas
    Angioli, Roberto
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 312 - 317
  • [7] Mutations in the PIK3 Pathway as a Major Determinant of Trastuzumab Resistance in Uterine Serous Carcinoma
    Black, Jonathan
    Lopez, Salvatore
    Schwab, Carlton
    English, Diana
    Santin, Alessandro
    REPRODUCTIVE SCIENCES, 2015, 22 : 77A - 77A
  • [8] Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma
    Black, J. D.
    Lopez, S.
    Bellone, S.
    Schwab, C. L.
    English, D. P.
    Roque, D. M.
    Silasi, D. A.
    Ratner, E. S.
    Azodi, M.
    Rutherford, T. J.
    Schwartz, P. E.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 161 - 162
  • [9] Alterations in PTEN/PIK3CA/AKT pathway does not modify trastuzumab response in HER-2/NEU breast carcinomas
    Lerma, E.
    Gallardo, A.
    Peiro, G.
    Planelles, M.
    Vergara, C.
    Solis, J.
    Dominguez, N.
    Alonso, C.
    Barnadas, A.
    Prat, J.
    HISTOPATHOLOGY, 2008, 53 : 47 - 48
  • [10] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
    Rexer, B. N.
    Chakrabarty, A.
    Rinehart, C.
    Chang, J.
    Engelman, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 266S - 267S
12345